Carsten Thiel, Biopharmaceutical CEO Extraordinaire

 

Carsten Thiel is the current CEO of Abeona Therapeutics Inc. He previously was the Chief Executive Officer at Amgen. Thiel has an extensive background in the pharmaceutical/ biopharmaceutical realm; he received a graduate degree from Philipps University of Marburg and a doctorate degree in molecular genetics at the Max-Planck-Institute.

 

Carsten Thiel began his career at a biotechnology company called Hoffman La-Roche. He meticulously worked his way up the ranks and after working at several biotech/pharmaceutical companies, he now finds himself as the CEO of Abeona. Abeona therapeutics is a company which develops gene and cell therapies for individuals with rare diseases.

 

Carsten was recently interviewed by Ideamensch, an interview platform for entrepreneurs, in which he shares his thoughts on his career and on entrepreneurship. Carsten believes that an important part of his success comes from collaborative effort.

 

Carsten Thiel encourages his co-workers/ team members and listens to their input. By facilitating passion in each position, the company will flourish. He has found that empathy and human connection are one of the most overlooked elements in business and science.

 

One trend that Carsten is most excited about is new technologies and how they are being melded with medicine to advance the medical field. An example that he gives is it took decades to decode the human genome; compared to the present day in which it can be decoded in four days. Carsten is focusing his efforts on developing biotechnologies for individuals who currently lack any kind of treatment.

 

In an interview with IdeaMensch entitled: “Carsten Thiel: Pharmaceutical & Biopharmaceutical Expert”, Thiel expressed that people in future generations will remember the present as the most transformative time in history, where we use science and biology not only to understand, but actually to treat, and eradicate diseases.

 

He believes that being the FIRST company to offer an innovative product to a subset of people, such as those with a certain disease, very important for success. Carsten compares this to the popularity of Lfyt and Uber, the first two rideshare companies; they are so successful because they were the first companies within the rideshare space.

 

More on https://www.karyopharm.com/about/board-of-directors/

 

Leave a Reply

Your email address will not be published. Required fields are marked *